Medical Device Cybersecurity Risk Assessment: A Guide for FDA Submissions

Connected medical devices continue to create new opportunities for innovation, but they also introduce cybersecurity risks that manufacturers must address throughout the product lifecycle. As software-enabled medical devices and Software as a Medical Device (SaMD) products become more common, FDA reviewers are placing greater emphasis on cybersecurity as part of overall device safety and effectiveness.

A cybersecurity risk assessment is a key component of the cybersecurity documentation supporting a medical device submission. It helps demonstrate that cybersecurity threats, vulnerabilities, and potential patient safety impacts have been identified, evaluated, and addressed through appropriate controls.

FDA cybersecurity expectations have evolved significantly in recent years. The agency’s premarket cybersecurity guidance emphasizes that cybersecurity should be addressed throughout the product lifecycle rather than treated as a standalone activity performed shortly before submission. Reviewers increasingly expect cybersecurity considerations to be incorporated into design controls, software development activities, verification testing, risk management processes, and post-market planning.

For manufacturers preparing a 510(k), PMA, or other premarket submission involving software or connected functionality, cybersecurity documentation is no longer a secondary consideration. FDA reviewers increasingly expect clear evidence showing how cybersecurity risks have been managed and how residual risks have been evaluated.

This guide explains the purpose of a medical device cybersecurity risk assessment, the key components FDA reviewers expect to see, common submission gaps, and practical steps for preparing reviewer-friendly documentation. Organizations working to strengthen their medical device cybersecurity compliance programs should understand these expectations early in development to help support submission readiness.

Why Cybersecurity Risk Assessment Matters for FDA Review

Cybersecurity vulnerabilities can create more than technical concerns. In many cases, they can affect device functionality, data integrity, availability, and ultimately patient safety.

For this reason, FDA reviewers evaluate cybersecurity as part of the overall assessment of device safety and effectiveness. Manufacturers are expected to demonstrate that foreseeable cybersecurity threats have been identified and that appropriate controls have been implemented to reduce associated risks.

A well-developed cybersecurity risk assessment helps show:

• What cybersecurity threats were considered
• Which vulnerabilities may affect the device
• How risks were evaluated
• What controls have been implemented
• How residual risks were assessed

Risk assessments also provide context for other cybersecurity documentation included in a submission. Security testing reports, software architecture information, vulnerability management activities, and Software Bill of Materials (SBOM) documentation are often reviewed together.

FDA reviewers are not simply looking for evidence that security controls exist. They want to understand why those controls were selected, what risks they address, and whether they are appropriate for the intended use and operating environment of the device.

When documentation lacks this level of clarity, reviewers may issue Additional Information requests seeking clarification or supplemental evidence. Responding to these requests can extend review timelines and create additional work for development, quality, and regulatory teams.

Organizations pursuing FDA 510(k) submission support often focus on identifying cybersecurity documentation gaps before submission to help reduce review friction and support a more efficient review process.

Threat Modeling and Its Role in Risk Assessment

Threat modeling is a structured process used to identify potential attack paths, security weaknesses, and areas where cybersecurity controls may be required.

Rather than focusing only on known vulnerabilities, threat modeling evaluates how an attacker could interact with the system and what outcomes could result from successful exploitation.

System architecture diagrams and data flow diagrams often provide important inputs to threat modeling activities. These visual representations help teams understand how information moves through the device and where security boundaries exist.

Threat modeling is often most effective when performed early in development and revisited as the design evolves. Conducting threat modeling activities only at the end of development may limit opportunities to address identified concerns efficiently.

Threat modeling supports risk identification, prioritization, control selection, security testing strategies, and documentation development. The outputs frequently become important inputs for risk management files, cybersecurity documentation packages, and submission readiness activities.

Threat modeling should also reflect the device’s intended use, operating environment, user interactions, and clinical context. Effective thread modeling begins by systematically analyzing the device, its operating environment, intended users, regulatory requirements, and other relevant factors to identify realistic sources of cybersecurity risk before evaluating potential threats and mitigations. These factors often influence both risk severity and mitigation decisions.

The outputs from threat modeling frequently influence security testing activities. Manufacturers should also document the thread modeling methodology used, whether based on established frameworks such as STRIDE or another methodology, so FDA reviewers can understand how threats were identified, analyzed, and prioritized. By identifying high-priority attack paths, manufacturers can focus testing efforts on the areas most relevant to device security.

Organizations conducting cybersecurity testing for FDA submissions should ensure testing activities align with threat modeling outputs and overall cybersecurity risk management objectives.

Key Components of a Medical Device Cybersecurity Risk Assessment

A cybersecurity risk assessment should provide a structured evaluation of the device’s cybersecurity posture and the controls used to manage identified risks. While the specific content may vary depending on the device and intended use, several elements are commonly expected.

Asset Identification

The assessment should begin with a clear understanding of what must be protected. This includes identifying:

• Software applications
• Firmware components
• User interfaces
• Network connections
• Data storage locations
• External systems and integrations
• Cloud-based services

Documenting system architecture and data flows helps establish the foundation for subsequent risk analysis activities.

Threat Identification

Manufacturers should identify foreseeable threats that could affect device security or performance.

Examples may include:

• Unauthorized access
• Malware attacks
• Credential compromise
• Data manipulation
• Denial-of-service events
• Loss of device or system availability

Threat identification should consider how the device may be used, where it will operate, and how attackers could potentially interact with the system. A comprehensive threat analysis helps ensure cybersecurity controls address realistic risks rather than theoretical concerns alone.

Vulnerability Identification

The next step is evaluating weaknesses that could be exploited by identified threats.

Potential vulnerabilities may include:

• Third-party software components
• Known software defects
• Misconfigurations
• Insecure communication methods
• Weak authentication mechanisms
• Unsupported software dependencies

Vulnerability analysis should include third-party software components and dependencies. Many manufacturers use Software Bill of Materials documentation to support vulnerability management and maintain visibility into software-related risks.

Risk Evaluation

Once threats and vulnerabilities have been identified, manufacturers should evaluate risk based on factors such as:

• Likelihood of exploitation
• Severity of impact
• Ease of attack
• Potential effect on device performance
• Potential impact on patients or users

Risk evaluation methods should be documented and applied consistently. Reviewers should be able to understand how likelihood, severity, exploitability, and patient impact influenced risk prioritization decisions.

Risk Controls

Risk controls may include technical safeguards, process controls, monitoring activities, and update mechanisms designed to reduce cybersecurity risk.

Examples include:

• Authentication controls
• Encryption
• Access restrictions
• Logging and monitoring
• Security patch processes
• Software update mechanisms

The effectiveness of cybersecurity controls should be supported by objective evidence whenever possible. Verification activities may include penetration testing, vulnerability scanning, code review, authentication testing, encryption validation, or other security-focused evaluations.

Controls should also be evaluated collectively rather than individually. In many cases, cybersecurity resilience depends on multiple layers of protection working together to reduce risk.

Residual Risk Evaluation

After controls have been implemented, manufacturers should evaluate any remaining residual risks. The rationale supporting residual risk acceptability should be documented and aligned with the organization’s overall risk management approach.

Residual risk discussions often receive significant attention during review because they reflect the organization’s final assessment of cybersecurity acceptability. Manufacturers should clearly explain how residual risks were evaluated and why they are considered acceptable within the context of the device’s intended use.

Traceability

One of the most important aspects of cybersecurity documentation is traceability. Reviewers should be able to follow the relationship between identified risks, implemented controls, verification activities, and supporting evidence.

Strong traceability demonstrates that risks have been systematically addressed rather than managed through isolated activities. Organizations preparing cybersecurity documentation for FDA submissions should ensure these relationships are clearly documented throughout the submission package.

Risk Assessment Methods and FDA Expectations

FDA cybersecurity review follows a risk-based approach. In simple terms, this means manufacturers should focus resources on identifying and addressing the cybersecurity risks that matter most for device safety and effectiveness.

Cybersecurity risk assessment activities should not be conducted independently of broader medical device risk management activities. Instead, cybersecurity considerations should be integrated into the organization’s overall risk management framework.

Several commonly referenced standards and guidance documents may support these efforts, including:

• ISO 14971
• AAMI TIR57
• FDA premarket cybersecurity guidance
• Secure product development frameworks

Regardless of the methodology used, consistency remains one of the most important factors during FDA review. Reviewers often evaluate multiple cybersecurity artifacts simultaneously, including risk assessments, threat models, testing reports, SBOM documentation, software descriptions, and risk management files.

When these documents use different terminology, inconsistent assumptions, or conflicting risk conclusions, reviewers may have difficulty following the overall cybersecurity narrative. Clear alignment across documentation packages helps improve review efficiency and supports a more streamlined evaluation process.

While methodologies may differ among organizations, FDA reviewers generally look for consistent logic and clear documentation. They are evaluating whether the submission clearly demonstrates what risks exist, how those risks were evaluated, what controls were implemented, how effectiveness was verified, and why residual risks are acceptable.

Organizations focused on broader medical device regulatory compliance should ensure cybersecurity documentation supports the overall submission narrative.

Common Cybersecurity Risk Assessment Gaps in Submissions

Cybersecurity sections often receive increased scrutiny during FDA review because documentation gaps can make it difficult for reviewers to assess risk management effectiveness.

Several issues appear repeatedly in submissions.

Incomplete Threat Identification

Some assessments focus on a limited set of threats while overlooking foreseeable attack vectors, user interactions, or operational scenarios.

Weak Connections Between Risks and Controls

Reviewers may struggle to understand how identified risks are addressed when controls are not clearly linked to documented threats and vulnerabilities.

Missing Traceability

Traceability gaps remain one of the most common documentation challenges. Reviewers should be able to connect risks, requirements, controls, testing activities, and conclusions.

SBOM Documentation Disconnects

Software Bill of Materials information is most useful when integrated into vulnerability management processes. Standalone SBOM documentation may leave important questions unanswered.

Testing Evidence Gaps

Security testing results should support identified risks and corresponding controls. Testing documentation that lacks context may create reviewer uncertainty.

Reviewer-Unfriendly Documentation

Technical documentation written exclusively for engineering audiences may not provide the clarity FDA reviewers need during submission evaluation.

Inconsistent Terminology

Different teams sometimes use different terms to describe the same cybersecurity concepts. Inconsistent terminology can create confusion and complicate review.

Organizations also sometimes struggle with documenting residual risk decisions. While technical teams may understand the reasoning behind risk acceptance decisions, those decisions are not always explained clearly within submission materials. FDA reviewers generally expect to see documented rationale supporting these conclusions.

Additional insights regarding common submission concerns can be found within QCC’s medical device regulatory FAQs.

How to Prepare a Cybersecurity Risk Assessment for FDA Submission

Strong cybersecurity documentation typically begins long before submission preparation starts. Manufacturers should also become familiar with FDA's cybersecurity guidance for medical device premarket submissions and the FDA's eSTAR electronic submission program early in the development process. These resources outline FDA's expectations for cybersecurity documentation and provide the standardized submission framework used for many medical device premarket submissions, helping teams prepare more complete and reviewer-friendly submissions. Cybersecurity activities should be incorporated throughout development rather than assembled at the end of the process. Several practices can help strengthen submission readiness.

Build Cross-Functional Alignment

Engineering, cybersecurity, quality assurance, and regulatory teams should collaborate throughout development to ensure documentation remains consistent and complete.

Create a Complete Asset Inventory

Document software components, interfaces, external connections, data flows, and system dependencies early in the development lifecycle.

Connect Supporting Activities

Cybersecurity risk assessment should align with threat modeling, vulnerability management, SBOM development, security testing, and risk management activities. These relationships should be clearly documented.

Focus on Traceability

Traceability helps reviewers understand how identified risks were addressed and verified. Strong traceability often improves reviewer usability and supports more efficient review.

Develop Reviewer-Friendly Narratives

Technical artifacts alone may not provide sufficient context. Clear narratives help explain the significance of risks, controls, testing activities, and conclusions.

Anticipate Reviewer Questions

Before submission, teams should evaluate documentation from a reviewer perspective and identify areas where additional clarification may be needed.

Many organizations benefit from performing internal readiness reviews before submission. These reviews help identify documentation gaps, traceability issues, inconsistent terminology, and areas where additional supporting evidence may be needed.

Submission readiness reviews can also evaluate whether cybersecurity documentation aligns with broader risk management activities, software documentation, and regulatory strategy. Identifying these issues before submission may help reduce review friction and improve the efficiency of responses if questions arise during FDA review.

Strengthening Cybersecurity for Successful Submissions

Cybersecurity risk assessment has become a central component of modern medical device submissions. FDA reviewers increasingly expect documentation that demonstrates how cybersecurity threats, vulnerabilities, controls, testing activities, and residual risks are addressed within a comprehensive risk management framework.

The strongest submissions provide clear traceability between identified risks, implemented mitigations, supporting evidence, and final risk conclusions. Well-organized documentation can help reduce review friction and support more efficient responses if questions arise during review.

Well-organized cybersecurity documentation can support more efficient review and help manufacturers respond more effectively to FDA questions. Organizations preparing cybersecurity submissions can contact our team for cybersecurity support to discuss strategies for improving submission readiness and supporting FDA review expectations.